With sub­par sales for Leqem­bi, Ei­sai de­lays Alzheimer’s pa­tient goal dead­line

Ei­sai said it could strug­gle to meet up­take tar­gets for its Bio­gen-part­nered Alzheimer’s drug Leqem­bi by the end of March as it de­tailed dis­ap­point­ing fis­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER